VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY

摘要

Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.

主权项

1. A method of reducing biological activity of C-X-C motif ligand 12 (CXCL12), comprising:
contacting stellate cells expressing CXCL12 with a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists, thereby reducing the biological activity of CXCL12.